Apigenin reduces the expression of multiple senescence-associated secretory phenotype (SASP) factors—including IL6, CXCL8, IL1α, and MMP1—in senescent human stromal cells in vitro and in prematurely aged mice, without eliminating senescent cells, and this reduction is associated with attenuated chronic inflammation and improved physical and cognitive function in animal models.

Apigenin binds to a protein called PRDX6 and blocks its ability to release a fatty acid called arachidonic acid. This stops a chain reaction that would normally turn short-term cell stress into long-term inflammation. Without this chain reaction, the cell stops releasing harmful inflammatory signals, even though it remains senescent. The reduction in these signals allows tissues to function better, improving strength and memory.